Drug treatment for LUTS and BPH: New is not always better

European Urology

Volumn 49, Issue 1, 2006, Pages 5-7

  Roehrborn, Claus G ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; BXL 353; BXL 628; CALCITRIOL; CALCITRIOL DERIVATIVE; CLUSTERIN; DNA FRAGMENT; DOXAZOSIN; DUTASTERIDE; FINASTERIDE; PHOSPHATE; PROSTATE SPECIFIC ANTIGEN; STEROID 5ALPHA REDUCTASE; STEROID 5ALPHA REDUCTASE 1; STEROID 5ALPHA REDUCTASE 2; STEROID 5ALPHA REDUCTASE INHIBITOR; TERAZOSIN; TESTOSTERONE; UNCLASSIFIED DRUG; VITAMIN D RECEPTOR;

ANDROGEN BLOOD LEVEL; APOPTOSIS; CALCIUM BLOOD LEVEL; CALCIUM URINE LEVEL; CELL PROLIFERATION; CLINICAL TRIAL; DISEASE COURSE; DISEASE SEVERITY; EDITORIAL; FLOW RATE; HUMAN; HYPERCALCEMIA; HYPERPHOSPHATEMIA; MONOTHERAPY; NONHUMAN; PHOSPHATE EXCRETION; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; QUALITY OF LIFE; SYMPTOM; TRANSURETHRAL RESECTION; URETHRA DISEASE; URINE RETENTION; URODYNAMICS;

ANIMALS; HUMANS; MALE; PROSTATIC HYPERPLASIA; URINATION DISORDERS;

EID: 29044449518     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.10.005     Document Type: Editorial

References (9)

1. B. Djavan, and M. Marberger A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction Eur Urol 36 1 1999 1 13
2. G.M. Clifford, and R.D. Farmer Medical therapy for benign prostatic hyperplasia: a review of the literature Eur Urol 38 1 2000 Jul 2 19
3. C. Roehrborn, and J. McConnell Etiology, Pathophysiology, Epidemiology and Natural History of Benign Prostatic Hyperplasia P. Walsh A. Retik E. Vaughan A. Wein Campbell's Urology 8th ed. 2002 Saunders Philadelphia 1297 1336
4. P. Boyle, C. Roehrborn, R. Harkaway, J. Logie, J. de la Rosette, and M. Emberton 5-Alpha reductase inhibition provides superior benefits to alpha blockade by preventing AUR and BPH-related surgery Eur Urol 45 5 2004 May 620 626 discussion 626-7
5. M. Emberton, G.L. Andriole, and J. de la Rosette Benign prostatic hyperplasia: a progressive disease of aging men Urology 61 2 2003 Feb 267 273
6. C.G. Roehrborn, M. Malice, T.J. Cook, and C.J. Girman Clinical predictors of spontaneous acute urinary retention in men with LUTS and clinical BPH: a comprehensive analysis of the pooled placebo groups of several large clinical trials Urology 58 2 2001 Aug 210 216
7. C. Crescioli, A. Morelli, and L. Adorini Human bladder as a novel target for vitamin D receptor ligands J Clin Endocrinol Metab 90 2 2005 Feb 962 972
8. C. Crescioli, P. Ferruzzi, and A. Caporali Inhibition of prostate cell growth by BXL-628, a calcitriol analogue selected for a phase II clinical trial in patients with benign prostate hyperplasia Eur J Endocrinol 150 4 2004 Apr 591 603
9. Enrico Colli, Patrizio Rigatti, Francesco Montorsi, Walter Artibani, Stefano Petta, Nicola Mondaini, et al.; and the BPH Italian Study Group. Bxl628, a novel vitamin d3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomised clinical tr. Eur Urol 2006.